Associations - EGFR exon 20 mutation

EGFR exon 20 mutation EGFR exon 20 mutation	Solid Tumor Solid Tumor	EGFR exon 20 mutation EGFR exon 20 mutation	Solid Tumor Solid Tumor	tarloxotinib bromide Sensitive: C2 – Inclusion Criteria	tarloxotinib bromide Sensitive: C2 – Inclusion Criteria
EGFR exon 20 mutation EGFR exon 20 mutation	Non Small Cell Lung Cancer NSCLC	EGFR exon 20 mutation EGFR exon 20 mutation	Non Small Cell Lung Cancer NSCLC	furmonertinib Sensitive: C2 – Inclusion Criteria	furmonertinib Sensitive: C2 – Inclusion Criteria
EGFR exon 20 mutation EGFR exon 20 mutation	Non Small Cell Lung Cancer NSCLC	EGFR exon 20 mutation EGFR exon 20 mutation	Non Small Cell Lung Cancer NSCLC	Immunotherapy Sensitive: C3 – Early Trials	Immunotherapy Sensitive: C3 – Early Trials
EGFR exon 20 mutation EGFR exon 20 mutation	Non Small Cell Lung Cancer NSCLC	EGFR exon 20 mutation EGFR exon 20 mutation	Non Small Cell Lung Cancer NSCLC	erlotinib Sensitive: C3 – Early Trials	erlotinib Sensitive: C3 – Early Trials
EGFR exon 20 mutation EGFR exon 20 mutation	Non Small Cell Lung Cancer NSCLC	EGFR exon 20 mutation EGFR exon 20 mutation	Non Small Cell Lung Cancer NSCLC	icotinib Sensitive: C3 – Early Trials	icotinib Sensitive: C3 – Early Trials
EGFR exon 20 mutation EGFR exon 20 mutation	Non Small Cell Lung Cancer NSCLC	EGFR exon 20 mutation EGFR exon 20 mutation	Non Small Cell Lung Cancer NSCLC	afatinib Sensitive: C3 – Early Trials	afatinib Sensitive: C3 – Early Trials
EGFR exon 20 mutation EGFR exon 20 mutation	Non Small Cell Lung Cancer NSCLC	EGFR exon 20 mutation EGFR exon 20 mutation	Non Small Cell Lung Cancer NSCLC	FCN-411 Sensitive: C3 – Early Trials	FCN-411 Sensitive: C3 – Early Trials